Litoxetine

Drug Profile

Litoxetine

Alternative Names: IXA 001; SL 810385

Latest Information Update: 16 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi-Synthelabo
  • Developer IXALTIS
  • Class Antidepressants; Piperidines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urinary incontinence
  • Discontinued Major depressive disorder

Most Recent Events

  • 15 Mar 2017 Phase-II clinical trials in Urinary incontinence in Georgia (PO)
  • 15 Mar 2017 IXALTIS receives approval from European Health Authorities via Europe's Voluntary Harmonisation Procedure to initiate a phase II trial in Europe
  • 15 Mar 2017 IXALTIS receives approval from Health Canada to initiate a phase II trial in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top